Celltrion

Últimas noticias

Titulares en el idioma original de la fuente.

• Celltrion obtains U.S. Phase 3 clinical trial approval for ‘Zymfentra’ seeking expansion for rheumatoid arthritis indications (se abre en una pestaña nueva)

  더바이오 · 2 oct 2026

• 셀트리온, 시밀러 제품군 "북유럽서 잇단 입찰수주" (se abre en una pestaña nueva)

  바이오스펙테이터 · 1 oct 2026

• Celltrion to Expand Global Supply Chain and CDMO Partnerships at CPHI, Accelerating Push to Become Global Drugmaker (se abre en una pestaña nueva)

  v.daum.net · 29 sept 2026

• Celltrion wins U.S. Phase 3 clinical trial approval for ‘Zymfentra’ in rheumatoid arthritis, expanding indications (se abre en una pestaña nueva)

  더바이오 · 27 sept 2026

• How Celltrion's Remsima Became Japan's Top Infliximab: A 2026 Market Analysis (se abre en una pestaña nueva)

  뉴스1 · 18 sept 2026

• Celltrion Submits U.S. Phase 4 IND for High-Dose 240 mg Zymfentra (se abre en una pestaña nueva)

  뉴스1 · 16 sept 2026

• Celltrion Launches U.S. Phase 4 Trial of High-Dose Zymfentra (se abre en una pestaña nueva)

  팜이데일리 · 15 sept 2026

• “Second-Half Performance to Outpace First Half”… Celltrion Expected to Exceed Full-Year Revenue Target (se abre en una pestaña nueva)

  뉴스1 · 4 sept 2026

• 
  Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength (se abre en una pestaña nueva)

  Business Wire · 24 ago 2026

• 
  Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW) (se abre en una pestaña nueva)

  PR Newswire · 21 abr 2026

• 
  Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation (se abre en una pestaña nueva)

  PR Newswire · 16 mar 2026

• 
  Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference (se abre en una pestaña nueva)

  PR Newswire · 14 ene 2026

• 
  Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference (se abre en una pestaña nueva)

  PR Newswire · 6 ene 2026

• 
  Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 (se abre en una pestaña nueva)

  GlobeNewswire · 6 ene 2026

• 
  Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers (se abre en una pestaña nueva)

  GlobeNewswire · 15 dic 2025

• 
  Exploring Three High Growth Tech Stocks with Global Potential (se abre en una pestaña nueva)

  Simply Wall St. · 12 nov 2025

• 
  Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases (se abre en una pestaña nueva)

  PR Newswire · 4 nov 2025